Experimental Hadassah-inspired pill is 'promising' in repairing cystic fibrosis gene

Substance may be able to help in the fight against cancer.

By
November 14, 2006 22:11
2 minute read.
Experimental Hadassah-inspired pill is 'promising' in repairing cystic fibrosis gene

pills 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

A new experimental oral medication for cystic fibrosis (CF) patients who carry a genetic mutation that affects 60 percent of all Jewish patients, most of which are of Ashkenazi origin, has been found "promising" by doctors at Hadassah University Medical Center on Jerusalem's Mount Scopus. This is the first time a pill has been given to correct the genetic malfunction that causes the body to stop producing the essential protein whose absence results in CF. The mutation in the CF transmembrane regulator gene known as "STOP" is present in more than 10% of CF patients worldwide. Developed by PTC Therapeutics of South Plainfield, New Jersey, the experimental treatment caused the CFTR type protein to return to its proper function. In addition, the lung function and overall well-being of most of the patients who participated in the clinical trial were significantly improved. CF is an inherited chronic disease that affects the lungs and digestive systems. The defective STOP gene contain signals that cause the CFTR protein to malfunction, leading to life-threatening lung infections and pancreatic insufficiency that stops natural enzymes from helping the body break down and absorb food. The results of the clinical trials conducted at Hadassah and five sites in the US indicate success in restoring CFTR function. Prof. Eitan Kerem, pediatrics chief at the hospital, and Dr. Michael Wilschanski, its director of pediatric gastroenterology, presented the initial data from the clinical trials earlier this month at the North American Cystic Fibrosis Conference in Denver. Hadassah was the only non-US medical center participant in PTC Therapeutics‚ clinical trial. The treatment and trial are based on research Kerem and Wilschanski successfully conducted three years ago, proving that giving Gentamicin antibiotic as nose drops for two weeks helped correct the genetic defect. "We were very gratified to see such remarkable improvements in CFTR function and other parameters in just a two-week treatment period," said Kerem. "We proved - for the first time in patients - that it is possible to correct genetic defects using a simple treatment. Based on this clear demonstration of PTC124 activity, we have initiated a three-month study to further evaluate its potential for improving patient treatment." This study will be carried out within the framework of a longer Phase 2b cystic fibrosis program conducted by Hadassah and PTC Therapeutics. Hadasit Ltd., the Hadassah Medical Organization technology transfer company and subsidiary responsible for commercializing Hadassah's intellectual property and R&D capabilities in biomedical technology, formalized the agreement between Hadassah and PTC. Meanwhile, PTC Therapeutics announced Monday that it has begun a Phase 1 multiple-dose study to evaluate escalating dose levels of PTC299 in healthy volunteers. The substance has shown indications of working against cancer using the same core mechanism used against CF. It is believed to modulate RNA-mediated protein expression to inhibit the production of vascular endothelial growth factor (VEGF) in tumors.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM